Roche’s TAGS technology allows for the simultaneous identification of up to 15 targets in a single patient sample on the cobas 5800, 6800, and 8800 systems. Credit: Taljat David / Shutterstock.

Roche has received the CE mark certification for its newly updated cobas 6800/8800 systems 2.0, improving laboratories and testing capabilities.

The upgrade of the systems is set to optimise laboratory resources, decrease downtime, consolidate test menus, and increase throughput, offering more diagnostics experience for patients and healthcare professionals.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The cobas 6800/8800 systems are tailored to meet the needs of mid-to-high-volume molecular testing laboratories. They claim to offer intelligent workflows, performance, throughput, and established reliability and flexibility.

Temperature-activated generation of signal (TAGS) technology, along with most of the cobas test menu, is available with the release of the upgrade.

The company’s TAGS technology allows for the simultaneous identification of up to 15 targets in a single patient sample on the cobas 5800, 6800, and 8800 molecular diagnostic analyser systems.

It is designed to differentiate up to three targets per fluorescence channel. The technology surpasses the technical limitations of typical 4-plex test outcomes found in prior solutions, leveraging a new approach.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roche Diagnostics CEO Matt Sause said: “This update marks another significant milestone for Roche.

“With our history of leading innovation in automated molecular testing, it represents another competitive leap forward in our efforts to advance PCR technology by combining unprecedented throughput together with the flexibility that laboratories require to deliver for physicians and patients.”

Labs with existing cobas 5800, 6800, and 8800 systems can instantly deliver quick, precise, high throughput flexible syndromic multiplex PCR testing to central laboratories eliminating the need for hardware or software upgradation.

The upgrade also aligns the ‘cobas family of solutions’, offering a combined user experience including innovations from the cobas 5800 system.

Looking ahead, the company plans to seek 510(k) clearance from the US Food and Drug Administration (FDA), with submission expected in the coming year.

In November 2022, Roche received emergency use authorisation from the FDA for its mpox virus detection test, cobas MPXV, for use on the cobas 6800/8800 Systems.